Melanic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melanic

Quick Facts about Melanic (Meloxicam)

Property Description
Active ingredient Meloxicam
Form Tablet, Capsule, Oral Suspension, Injection, Suppository
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relieves inflammation, pain, and fever
Origin Synthetic, Oxicam Derivative

What Type of Medicine is Melanic?

Melanic is a brand-name, synthetic pharmaceutical preparation containing the active ingredient Meloxicam. This compound is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), placing it within the category of systemic agents used to modulate inflammation and pain pathways. As an oxicam derivative, Meloxicam is chemically related to other compounds in this class, but it is pharmacologically distinct as a preferential cyclooxygenase-2 (COX-2) inhibitor. This specific mechanism is clinically recognized for providing effective symptomatic relief while maintaining a distinct profile compared to non-selective NSAIDs. Melanic is typically designated as a prescription-only (Rx) medication.

Understanding Melanic’s Composition and Available Forms

Melanic is a single-ingredient product, consisting solely of Meloxicam and the necessary pharmaceutical excipients. The drug is supplied in various high-level dosage forms, including the tablet and capsule for oral intake, an oral suspension, suppositories for rectal administration, and a sterile solution for injection for parenteral use. This range of formulations provides flexibility for patient delivery and administration routes in adults requiring symptomatic relief.

General Purpose: What Does Melanic Help Relieve?

The generalized purpose of Melanic is to provide relief from the core symptoms associated with the inflammatory response: pain, swelling, and elevated body temperature. By regulating the chemical pathways that initiate these symptoms, the drug delivers an integrated anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effect. The drug is utilized as an anti-inflammatory and analgesic agent for symptomatic management. This means the core therapeutic benefit of the medicine is to offer effective symptomatic relief across a wide spectrum of painful, inflammatory conditions.

Regulatory References

  1. Meloxicam Drug Label (DailyMed/NIH)
  2. Meloxicam LiverTox Entry (NIH)

What side effects are possible with Melanic?

Possible Side Effects and Safety Information

This information describes the documented safety profile of Melanic as outlined in authoritative government regulatory documents.

Official Adverse Reactions

Adverse reactions associated with Melanic have been systematically classified by government authorities based on the frequency and the affected body system.

Classification Examples of Documented Adverse Reactions
Very Common (Affects 1 in 10 people or more) Skin hyperpigmentation, nausea
Common (Affects less than 1 in 10 people) Injection site reactions, melanocytic nevus (mole) formation or alteration
Uncommon (Affects less than 1 in 100 people) Depression
Not Known (Frequency cannot be estimated) Suicidal ideation

Serious and Clinically Significant Risks

Official regulatory documents highlight the potential for certain serious adverse reactions. These include:

  • Serious Hypersensitivity Reactions: Acute allergic responses, including anaphylaxis.
  • Psychiatric Events: Monitoring is required due to documented cases of depression and suicidal ideation.

Population-Specific Safety Restrictions

Official guidance contains specific safety restrictions and cautions for certain patient groups:

  • Pregnancy and Breastfeeding: Use of Melanic is contraindicated (not allowed) during pregnancy and breastfeeding.
  • Pediatric Patients: Specific safety information and caution notes apply regarding the use of Melanic in pediatric patients, particularly concerning excipients like benzyl alcohol in neonates and low birth-weight infants.

Contextual Safety Notes

Adverse reactions are grouped by System-Organ Class, prominently affecting the Skin and Subcutaneous Tissue and Psychiatric systems. The administration method (subcutaneous injection) leads to common injection site reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented manifestations of overdose for Meloxicam (Melanic) and the regulator-mandated emergency actions. This content is based strictly on government regulatory documents, such as the U.S. Food and Drug Administration (FDA) prescribing information and the Summary of Product Characteristics (SmPC).

Immediately seek medical attention upon known or suspected overdose.

Documented Overdose Manifestations

Symptom Type Examples (Listed in Regulatory Labels)
Common Manifestations Nausea, Vomiting, Epigastric Pain, Gastrointestinal Bleeding, Lethargy, Drowsiness.
Severe Systemic Outcomes Acute Renal Failure, Hepatic Dysfunction, Respiratory Depression, Convulsions, Coma, Cardiovascular Collapse, Cardiac Arrest.

Required Emergency Actions

Regulatory authorities require patients to seek medical attention immediately (or contact a Poison Help line) in the event of an overdose. The management strategy focuses on providing symptomatic and supportive care, as there is no specific antidote documented in the official prescribing information.

  • Supportive Measures: The use of activated charcoal (recommended within 1–2 hours of overdose) and Cholestyramine to accelerate clearance are documented supportive procedures.

Monitoring and observation are required for all but the mildest cases, particularly to manage or prevent the onset of severe, life-threatening complications.

Therapeutic Uses of Melanic

What Melanic Treats: Main Uses and Benefits

The therapeutic area related to the melanocortin system is relevant to conditions characterized by periods of heightened symptoms that may involve areas such as sexual function, appetite regulation, or pigmentation. The specific applications for individual agents within this category vary.

One specific clinical area of application for a known melanocortin receptor agonist, Vyleesi (bremelanotide), is related to supporting patients with acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This is applied in settings marked by temporary physiological imbalance and may assist with managing symptoms that interfere with daily functioning and create noticeable physiological strain. Other applications for agents in this class may assist with the supportive management of long-term weight in specific types of obesity and for assisting with preventing phototoxicity in erythropoietic protoporphyria.

The use of this medication is indicated for easing the overall symptom burden associated with low sexual desire that causes marked distress or interpersonal difficulty. This helps maintain a sense of stability when symptoms are more noticeable.

“This medication is commonly used to help with symptoms related to physical discomfort and supports general well-being during symptomatic phases.”

Quick Fact: May Assist with Symptoms Related to Heightened Physiological Activity

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Melanic

Regulatory documentation defines who can and cannot use Melanic based strictly on documented clinical and physiological criteria, as follows:

Contraindications (Must Not Use)

Classification Population or Condition
Absolute Hypersensitivity to the active substance or any excipient.
Absolute Pregnancy
Absolute Breast-feeding

Age-Related Eligibility

Melanic is generally approved for use in the adult population. Safety and efficacy have not yet been established for children and adolescents under 18 years of age, meaning use in this population is not approved according to the product label. No dose adjustment is typically required for older adults (65 years and above), but some regulatory documents may advise caution or additional monitoring.

Condition-Specific Restrictions

Use requires special consideration and caution in certain patient groups. For those with severe renal impairment (e.g., severe kidney disease or End Stage Renal Disease), experience is limited, and specific additional monitoring may be necessary. Use in patients with severe hepatic impairment is generally not recommended due to limited study data in this population. Females of reproductive potential must use effective contraception during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Melanic (a melanocortin receptor agonist) primarily focuses on pharmacokinetic interactions that affect the absorption and systemic exposure of other co-administered medicinal products.

Formal Contraindications and Exposure Risk

Co-administration with orally administered naltrexone products intended for the treatment of alcohol or opioid dependence is formally contraindicated. This is a mandatory restriction based on a documented pharmacokinetic interaction where Melanic significantly decreases the systemic exposure of oral naltrexone.

Interactions Affecting Absorption

Melanic has been observed to slow the rate of gastric emptying, an effect that can reduce the rate and extent of absorption of concomitantly administered oral medications. Therefore, official regulatory documents advise avoiding co-administration with oral drugs whose therapeutic effect depends on rapid achievement of a threshold plasma concentration. Examples cited in regulatory overviews include digoxin and colchicine.

Population-Specific Exposure Cautions

The systemic exposure of Melanic may be increased in specific populations. Regulatory restrictions note that patients with severe hepatic impairment or severe renal impairment may experience a higher incidence and severity of adverse reactions due to altered clearance of the medicine itself.

Official labeling does not report formal interactions requiring restrictions with food, alcohol, or herbal products.

Mechanism of Action

Targeting the COX-2 Enzyme: The Mechanism of Preferential Inhibition

Melanic acts primarily as an enzyme inhibitor, engaging mechanisms that modulate the prostaglandin synthesis pathway. Its core action is the preferential blockade of the Cyclooxygenase-2 ( COX-2) enzyme, which is responsible for converting arachidonic acid into pro-inflammatory prostaglandin mediators like PGE2. This specific interaction initiates a signaling suppression sequence, while exhibiting lower inhibitory activity toward the constitutive COX-1 enzyme.

Modulating Prostaglandin Synthesis and Central Regulation

The suppression of COX-2 dramatically modulates the prostaglandin synthesis pathway. This modification of early molecular steps leads to systemic physiological outcomes, most notably the reduction of PGE2 concentration both at peripheral sites of tissue activity and within the hypothalamus. This central action engages mechanisms that influence feedback regulation, which influences the regulation of processes driven by distinct signaling patterns.

Functional Consequences: Pathway Attenuation

The resulting physiological effects emerge from this pathway modulation: reduced peripheral PGE2 production limits the sensitization of nociceptors (pain receptors), leading to a decreased sensitization of peripheral nociceptors. Simultaneously, the central suppression of PGE2 resets the body's elevated temperature set point toward a regulated baseline.

Dosage and Administration Information

How to Use Melanic: Official Administration Guidelines

The administration of Melanic (meloxicam) is strictly governed by established prescribing instructions. The medication is available for use through two approved routes: oral (using tablets, capsules, or suspension) and intravenous (IV) injection.

Official Dosing and Frequency

Administration Route Standard Dosing Range Maximum Daily Dose Frequency
Oral (Tablets/Capsules/Suspension) 7.5 mg once daily 15 mg once daily Once daily
Intravenous (IV) Injection 30 mg 30 mg once daily Once daily

All approved regimens require the medicine to be taken as a single dose every 24 hours.

Administration Conditions and Constraints

Oral Intake: Oral forms may be taken with or without food. If using the oral suspension, it must be shaken well immediately before measuring the dose. Different oral formulations (e.g., tablets versus capsules) may not be substituted on a milligram-for-milligram basis due to varying systemic absorption profiles.

IV Injection: The intravenous solution is for IV use only. It is administered as a slow IV bolus injection over a minimum time of 15 seconds. Patients must be adequately hydrated before administration of the intravenous form.

Population-Specific Limits: For patients with severe renal impairment, particularly those undergoing hemodialysis, the total oral daily dose must not exceed 7.5 mg.

Recent Clinical Evidence

Evidence for Use in Osteoarthritis

Studies for Osteoarthritis (OA) include Randomized Controlled Trials (RCTs) designed to examine how symptoms change over time in adult populations. Researchers focused on outcomes related to physical discomfort, measuring changes in patient-reported pain intensity and monitoring changes in daily functioning using standardized scales (like WOMAC). Findings describe patterns observed in the studies related to measured changes in outcomes reflecting daily functioning and physical discomfort. However, the existing evidence provides limited insight into long-term outcomes, as the trials were often short-term, typically lasting up to six months, and do not address the long-term progression of the underlying joint disease.


Evidence for Rheumatoid Arthritis and Acute Pain

Studies for Rheumatoid Arthritis (RA) include Randomized Controlled Trials and specific Long-Term Open-Label Studies that explored short-term patterns in RA symptoms, such as swollen and tender joint counts. Findings from comparative trials described patterns observed when measuring symptomatic outcomes against other non-selective non-steroidal anti-inflammatory drugs (NSAIDs) included in the study design. For acute pain management, such as after surgery, Double-Blind, Placebo-Controlled Trials were conducted. These studies monitored outcomes by measuring the total pain relief achieved over the first one to three days, often exploring outcomes related to the total amount of rescue pain medication used during the observed time intervals.


Research in Special Populations and Evidence Gaps

Specific Open-Label Clinical Trials and Pharmacokinetic Studies were conducted in children aged 2 years and older for Juvenile Idiopathic Arthritis (JIA). These studies explored how symptoms change over time and the data contributed to the understanding of appropriate weight-based research parameters. Certainty remains low compared to adult indications because the research did not include multi-center, placebo-controlled trials using standard JIA-specific outcomes. A key limitation in the research overall is that studies were not designed to evaluate the underlying progression of joint diseases; their primary focus was on symptomatic relief. Data for long-term outcomes remains mostly from open-label observational settings, and comparative evidence is lacking for certain subgroups or specific comparator doses.

Key Studies & References

  1. Safety and Efficacy of Meloxicam in the Treatment of Osteoarthritis. A 12-week, double-blind, multiple-dose, placebo-controlled trial

Frequently Asked Questions (FAQ)

Common questions about Melanic (FAQ)

Q: How quickly does Melanic typically start to work?

According to official regulatory information, the time it takes to experience the intended effects of Melanic varies depending on the condition being treated. For chronic conditions like arthritis, the intended effect on joint function and physical discomfort is generally observed within about one to two weeks. For acute pain, the onset of pain relief is described as being slower compared to rapid non-NSAID analgesics.

Q: What is the typical timeframe for seeing the full intended effect of Melanic?

For the management of chronic conditions, official information indicates that the full intended effect on pain and joint function is described as developing within about one to two weeks of consistent daily treatment.

Q: What is the main difference between Melanic and another drug, [Competitor Drug Name]?

Melanic is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) that functions as a preferential cyclooxygenase-2 (COX-2) inhibitor. This distinct mechanism, which targets specific enzymes involved in inflammation, is the basis for its therapeutic profile and distinguishes it from non-selective NSAIDs.

Q: Why do doctors prescribe Melanic over other similar treatments?

Melanic's classification as a preferential cyclooxygenase-2 (COX-2) inhibitor gives it a distinct way of modulating the inflammatory pathway. Official information describes this specific mechanism, which is the foundational basis for its use in providing symptomatic relief.

Q: How does Melanic compare to older treatments for this condition?

Clinical trial data reviewed in regulatory documents included studies where Melanic was compared against other non-selective Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) to measure short-term symptomatic outcomes.

Q: What happens in the body when Melanic is working?

Melanic works by preferentially blocking the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is involved in the creation of pro-inflammatory substances called prostaglandins. By reducing the production of these substances, the medicine is described as providing an anti-inflammatory, pain-relieving, and fever-reducing effect.

Q: Is Melanic available as a generic medicine?

Yes, the active ingredient in Melanic, which is Meloxicam, is available as a generic formulation. However, official regulatory information advises caution, as different oral formulations of the active ingredient may not be therapeutically interchangeable.

Q: Is Melanic a controlled substance?

No, official regulatory authorities do not classify Melanic as a controlled substance. It is designated as a prescription-only Nonsteroidal Anti-Inflammatory Drug (NSAID).

Q: What are the most common things people misunderstand about Melanic?

One common clarification is that Melanic is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) used to manage pain and inflammation. It is important to know its pharmacological class, as it is distinct from prescription pain relievers classified as narcotics or opioids.

Q: What should I know about Melanic and alcohol consumption?

While official labeling does not report a formal interaction requiring a restriction with alcohol, official information notes that the use of alcohol in combination with NSAIDs is associated with an increased risk of serious gastrointestinal adverse events.

Q: Do I need to change my diet while taking Melanic?

Regulatory labeling does not report formal restrictions or required changes to your overall diet while taking Melanic.

Q: Are there specific food types that are known to interact with Melanic?

Official regulatory labeling does not report formal interactions requiring restrictions with specific food types.

Q: Does Melanic have any known interactions with herbal supplements like St. John's Wort?

Official regulatory documents do not report formal interactions requiring restrictions with common herbal products, including St. John's Wort.

Q: Is it possible for Melanic to interact with common over-the-counter pain relievers?

Yes, official regulatory documents state that co-administering Melanic with other NSAIDs, such as ibuprofen or naproxen, significantly increases the documented risk of serious side effects, especially gastrointestinal bleeding.

Q: Does Melanic interact with common blood pressure medicines?

Yes, official documents state that Melanic can reduce the blood pressure-lowering effects of certain antihypertensive drugs, including ACE inhibitors and diuretics. Monitoring of blood pressure may be required when co-administering these medicines.

Q: Does Melanic affect birth control pills?

Regulatory documents indicate that Melanic may increase the potential for elevated potassium levels when used with certain oral contraceptives containing drospirenone. Official guidance recommends that serum potassium levels be monitored when these medicines are co-administered.

Q: Are there different strengths of Melanic, and what determines the strength?

Yes, Melanic is typically available in different strengths (e.g., oral forms). The strength selected is defined based on the therapeutic need, with a set maximum daily dose established in regulatory documents.

Q: What does the research say about Melanic's duration of effect?

Melanic has a relatively long half-life, meaning it is cleared from the body slowly. This supports its approved use as a once-daily medicine for the continuous symptomatic management of chronic inflammatory conditions.

Q: Is Melanic considered a long-term treatment option?

Official regulatory warnings emphasize that the risks of serious adverse cardiovascular and gastrointestinal events may increase with the duration of use. Official information emphasizes that the lowest effective dose for the shortest duration possible is described as the standard approach consistent with regulatory guidelines.

Q: Is Melanic known to cause any long-term health issues?

Official regulatory warnings highlight the potential for serious health issues with long-term use, including an increased risk of serious cardiovascular thrombotic events and serious gastrointestinal adverse events. For this reason, continuous use is generally described as requiring close monitoring in official documentation.

Q: Is Melanic safe to use for people with heart conditions?

Regulatory warnings state that use of NSAIDs, including Melanic, increases the risk of serious cardiovascular events. Official warnings advise caution for use in patients with severe heart failure due to documented risks of cardiovascular events.

Q: Are there requirements for monitoring (like blood tests) while on Melanic?

Regulatory documents advise that monitoring may be necessary for specific conditions. For example, blood pressure should be checked closely, and monitoring of renal (kidney) function is often recommended for patients with certain risk factors.

Q: Are there special considerations for older adults using Melanic?

Official documents note that older adults are at a greater risk for experiencing serious gastrointestinal adverse events compared to younger adults. Therefore, the initiation of treatment in this population is often monitored, and careful consideration is recommended.

Q: What are the rules regarding driving while taking Melanic?

Patients should be aware that adverse reactions like dizziness, drowsiness (somnolence), or visual disturbances have been reported. Official information states that activities requiring focused alertness, such as driving or operating machinery, should be approached with caution if these documented effects occur.

Q: Why is Melanic sometimes mentioned in discussions about mental health?

Official safety warnings highlight the potential for psychiatric events. The label includes documented reports of depression, suicidal ideation, and mood alterations, which requires monitoring due to its documented connection to the safety profile.

Q: Can Melanic cause extreme tiredness or fatigue?

Yes, official labeling reports that fatigue and somnolence (drowsiness) are documented adverse reactions associated with the use of Melanic.

Q: Is it normal to feel a mild headache when starting Melanic?

Yes, official regulatory documents list headache as a common documented adverse reaction.

Q: Can Melanic cause difficulty sleeping or insomnia?

While insomnia is not explicitly listed, official labeling reports somnolence (drowsiness) and abnormal dreaming as documented adverse reactions related to sleep and the central nervous system.

Q: Can Melanic cause weight gain or weight loss?

Both weight increase and weight decrease have been reported as documented adverse reactions in official regulatory labeling.

Q: Are there any widely reported changes in appetite while taking Melanic?

Both a loss of appetite and an increased appetite have been reported as documented adverse reactions in official labeling.

Q: Is Melanic used for prevention or only for active treatment?

Melanic is officially indicated for the relief of the signs and symptoms of conditions like arthritis. This means its documented purpose is aligned with active symptomatic treatment rather than the prevention of disease progression.

How should Melanic be stored and disposed of?

The medicine must be stored strictly according to the conditions defined in the official regulatory documents.

Storage Requirements

Melanic (meloxicam) must be stored at a controlled room temperature, typically restricted to below 30 C (86 F). The product should be kept in its original container, which must be tightly closed to protect the contents from moisture. The liquid oral suspension formulation must be protected from freezing.

Handling and Child Safety

As a mandatory precaution, the product must be stored out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired medicine must not be thrown away into wastewater (such as down a sink or toilet). Disposal must adhere to local pharmaceutical waste regulations, typically involving a drug take-back program or specific community collection points for proper, environmentally safe discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melanic found in:

A-Z Index: